《南科大讲堂 第435期》ZENG Musheng 教授：EBV疫苗的分子基础与发展策略

以下内容根据公开信息整理，并经大模型处理生成，可能存在疏漏或误差，请以实际信息为准。

  • 题目: EBV疫苗的分子基础与发展策略
  • 主讲人：ZENG Musheng 教授 @ Sun Yat-sen University Cancer Center
  • 时间：2026年4月23日 15:30-17:30
  • 地点：Conference Center, 4th Floor, Round Conference Room

主讲人简介

Professor Musheng Zeng, an Academician of the Chinese Academy of Sciences, is Deputy Director / Vice President of Sun Yat-sen University Cancer Center, President of the International Association for Research on Epstein-Barr Virus and Associated Diseases (IARE-BV), Director of Guangdong Engineering Research Center for Tumor Immunology and Vaccines, and Chair of the 2024 Gordon Research Conference on Nasopharyngeal Carcinoma. He has been selected into national high-level talent programs, the “Southern Guangdong Hundred Talents Program”, and awarded as one of the Ninth Batch of National Outstanding Young and Middle-Aged Experts with Outstanding Contributions in Health. He has received the National Science Fund for Distinguished Young Scholars, led two projects under the National Key Research and Development Program, and been principal investigator of multiple Key Programs of the National Natural Science Foundation of China. Professor Zeng has long been engaged in research on the oncogenic mechanisms of Epstein-Barr virus (EBV) and targeted intervention strategies. He was the first to identify the universal receptor for EBV infection, elucidated the mechanisms of EBV infection and oncogenesis, established an innovative EBV vaccine system, developed multiple vaccine candidates, and signed agreements for the translational application of research achievements. As corresponding or co-corresponding author, he has published more than 80 papers in leading international journals including Nature (2), Nature Microbiology (2), Cell Host & Microbe, Cell Research, Cancer Cell, Lancet Digital Health, PNAS, and Journal of Clinical Investigation. As the first completer, he received the Second Class Prize of the State Natural Science Award (2023), the First Class Prize of Natural Science from the Ministry of Education (2022), the First Class Prize of Natural Science of Guangdong Province (2018, 2023), and the First Class Science and Technology Award of the Chinese Anti-Cancer Association (2019).

讲座简介

EBV is a major causative agent of malignant tumors including nasopharyngeal carcinoma (NPC), yet the mechanism by which EBV infects epithelial cells has long remained elusive. Addressing key technological bottlenecks in the precise prevention and control of EBV-associated nasopharyngeal carcinoma, this study first elucidates the mechanism whereby multiple receptors (EphA2, NRP1, etc.) cooperatively mediate EBV infection of epithelial cells, and identifies R9AP as a universal receptor, along with its synergistic action with HLA II and EphA2. Secondly, it reveals a novel mechanism through which EBV induces cellular plasticity (epithelial immune dual phenotype, epithelial mesenchymal transition) via epigenetic regulation, thereby promoting immune evasion and metastasis. On this basis, fully human monoclonal antibodies and novel candidate vaccines have been developed, and preclinical studies have demonstrated their efficacy in effectively blocking viral infection. Finally, a highly sensitive CRISPR/Cas12a based detection platform named SENSORS has been established, which, combined with machine learning, improves the performance of early diagnosis. Collectively, this study provides theoretical basis and technical support for vaccine development and early screening of EBV associated tumors.

海报链接